Ipilimumab Administered to Stage IIIC Stage IV Melanoma After Reg. T Cell Depletion With Denileukin Diftitox
Status:
Terminated
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
This is an open-label, clinical efficacy study of Ipilimumab in patients with Stage IIIC and
Stage IV melanoma who have recently been treated with Denileukin Diftitox. Approximately 42
patients with radiographically measurable melanoma who have received at least one cycle of
Denileukin Diftitox will be enrolled and treated in the study.
Phase:
Phase 2
Details
Lead Sponsor:
James Graham Brown Cancer Center University of Louisville
Collaborators:
James Graham Brown Cancer Center University of Louisville